Deal Details

Sale to Vitruvian Partners

---

Summary

About

Phlexglobal (“Phlexglobal” or the “Company”), a portfolio company of Bridgepoint Development Capital (“BDC”), was recently acquired by Vitruvian Partners (“Vitruvian”). Terms of the transaction were not disclosed.

Phlexglobal is a leading provider of electronic Trial Master File (“eTMF”) solutions for global clinical trials, and has been central to the maturation of trial master files across the industry through participation in the creation of the TMF Reference Model. With approximately 70 active clients including 26 of the top 50 pharmaceutical companies, Phlexglobal is recognized as a global TMF specialist. The Company’s cloud-based, fully configurable PhlexEview eTMF platform supports its full service offerings. Phlexglobal is headquartered in Amersham, the United Kingdom and operates from five offices, across the United States, the United Kingdom and Poland.

Bridgepoint Development Capital provides funding to businesses headquartered in France, the Nordic region and the United Kingdom operating from offices in London, Paris and Stockholm. It is part of Bridgepoint, the international private equity group, which invests in businesses valued between €20 million and €1 billion from a network of offices globally. BDC is currently investing BDC III, a £600 million fund focused on investments in fast growing businesses in Europe valued up to £150 million. BDC is headquartered in London, the United Kingdom

Vitruvian is an independent private equity firm which specializes in growth middle-market investments. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries spanning information technology, life sciences & healthcare, media, and financial, business and consumer services. Vitruvian is currently investing the Vitruvian Investment Partnership II, which closed in December 2013 at its self-imposed cap of £1 billion. Vitruvian is headquartered in London, the United Kingdom.

---

For additional information about this transaction, please contact: